Oral Drug Delivery Market - Controlled and Sustained Release to be Major Revenue Generators
Publisher Name » GBI Research
Published Date » 2010-11-15
No. Of Pages » 85
GBI Research's report, “Oral Drug Delivery Market - Controlled and Sustained Release to be Major Revenue Generators”, provides the key data and analyzes the major challenges and drivers for the Oral Drug Delivery Market. The report also provides in-depth analysis of unmet needs, drivers and barriers that impact the global Oral Drug Delivery Market.
Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. The report is based on proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts to provide a comprehensive view of the Oral Drug Delivery Market.
Scope
- The scope of this report includes:
- Opportunities and challenges for Oral Drug Delivery Market in the pharmaceuticals industry
- Market revenues and forecasts for Oral Drug Delivery Market in the global pharmaceutical industry from 2009 to 2016.
- The key geographies including the US, Europe, Japan and Emerging Hotspots such as India, Singapore and China.
- Technology trends in Oral Drug Delivery Market. that shape the industry
- Qualitative analysis of the market drivers, barriers, future outlook and challenges for the Oral Drug Delivery Market.
- Analysis of competitive landscape and the leading market players.
Reasons to buy
- The report will enhance your decision making capability. It will allow you to:
- Formulate strategies to increase your company’s growth by understanding the new growth opportunities in Oral Drug Delivery Market.
- Differentiate yourself from competitors and develop new solutions for Oral Drug Delivery Market by understanding the current competitive landscape and how it is evolving to meet the increasing demands
- Draft efficient strategies by understanding best practices, identifying key winners and losers and who is best positioned to take advantage of the emerging market opportunities.
- Make more informed business decisions from the insightful and in-depth analysis of the market for biomanufacturing by analyzing the key technology trends that shape the growth of this market
Table of Contents
1 Table of Contents 3
1.1 List of Tables 7
1.2 List of Figures 8
2 Oral Drug Delivery Market Introduction 9
2.1 GBI Research Report Guidance 9
3 Oral Drug Delivery Market Overview 10
3.1 Global Drug Delivery Market 10
3.2 Drug Delivery as an Essential Component of the Pharmaceutical/Biotechnology Industry 10
3.2.1 Role of Drug Delivery in the Pharmaceutical Market 11
3.3 Patent Expirations and Their Effect on the Pharmaceutical Industry 13
3.3.1 Risk of Lost Sales for Major Pharmaceutical Companies Due to Patent Expiries 14
3.4 Repositioning of Existing Drugs through Reformulations - A Major Lifecycle Management Strategy 15
3.4.1 Repositioning of Marketed or Failed Drugs 15
3.4.2 Repositioning Through Reformulation 16
4 Market Overview - Introduction To The Oral Drug Delivery Market 18
4.1 Comparative Analysis of Oral Drug Delivery with Other Drug Delivery Forms 18
4.2 Oral Drug Delivery Enhanced/Enabled Products - Overview 20
4.2.1 Oral Drug Delivery Product Development Parameters 20
4.2.2 Market Exclusivity for Oral Drug Delivery Enhanced/Enabled Products 20
4.2.3 Major Therapeutic Areas for Oral Drug Delivery Enabled/Enhanced Products 21
5 Technology Landscape - Reformulating Injectable Drugs For Oral Delivery 22
5.1 Technologies Used in Oral Delivery of Peptides and Proteins 22
5.1.1 Oral Delivery Strategies of Peptides and Proteins - Chemical Modifications of Peptides and Protein Drugs 22
5.1.2 Oral Delivery Strategies of Peptides and Proteins - Enzyme Inhibitors 23
5.1.3 Oral Delivery Strategies of Peptides and Proteins - Absorption Enhancements 23
5.1.4 Oral Delivery Strategies of Peptides and Proteins - Using Mucoadhesive Polymers 24
5.1.5 Diabetes and Metabolic Disorders 25
5.1.6 Cardiovascular-related Disorders 27
5.1.7 Osteoporosis/Osteoarthritis and Bone Related Disorders 27
5.1.8 Central Nervous System Related Disorders 30
5.1.9 Oncology 30
5.2 Innovations Related to Oral Vaccine Development 31
5.2.1 Oral Vaccine Research Based Study - Live Bacterial Vectors 32
5.2.2 Oral Vaccine Research Based Study Use of Particulate Formulations 32
5.2.3 Oral Vaccine Research Based Study Use of Non-Toxic Mucosal Adjuvants 32
5.2.4 Oral Vaccine Research Based Study-Transgenic Plants 33
6 Technology Landscape - Nanotechnology in Drug Delivery 34
6.1 Introduction 34
6.2 Application of Nanotechnology 34
6.2.1 NanoDRY and NanoCOAT Technology 34
6.2.2 Polymeric Nano-Delivery System (PNDS) 35
6.2.3 FluidCrystal NP Oral Nanoparticles 35
6.2.4 NanoCrystal Technology 36
7 Technology Landscape - Advances in Oral Prodrug Delivery 37
7.1 Targeted Prodrug Design 37
7.1.1 Prodrug Design Targeting Enzymes 37
7.1.2 Prodrug Design Targeting the Membrane Transporters 39
7.2 Featured Prodrugs- Anti-Viral 41
7.2.1 Oseltamivir 41
7.2.2 Valganciclovir 41
7.2.3 Famciclovir 42
7.2.4 Cidofovir 42
7.2.5 Zanamivir 42
7.3 Respiratory Prodrugs 43
7.3.1 Bambuterol 43
7.4 Featured Prodrugs - Anti-Cancer 43
7.4.1 Gemcitabine 43
7.5 Featured Prodrugs - Central Nervous System 43
7.5.1 Levodopa 43
7.5.2 LY2140023 44
7.6 Featured Prodrugs- Antibiotics 44
7.6.1 Torezolid Phosphate 44
8 Technology Landscape - Advances in Delayed and Controlled Release Delivery 45
8.1 Controlled Release Oral Drugs 45
8.1.1 Dissolution Controlled Release 46
8.1.2 Diffusion Controlled Release 46
8.1.3 Diffusion and Dissolution Controlled Systems 46
8.1.4 Ion-exchange Resins 46
8.1.5 pH - Independent Formulations 46
8.1.6 Osmotically Controlled Release 46
8.1.7 Altered Density Formulations 47
8.1.8 Types of Tablets Formulations Possible for Controlled Release Oral Drugs 47
8.1.9 Challenges and Advantages for Controlled Release Oral Drug Delivery Systems 48
8.1.10 Key Future Applications of Controlled Release Platforms for Oral Therapeutics 49
8.1.11 Orally Disintegrating Tablets 50
8.1.12 Minitablets as a Flexible Drug Delivery System. 50
8.1.13 Taste Masking Technologies for Bitter Tasting Oral Drugs 50
9 Therapeutic Landscape Oral Drug Delivery Systems Across Major Therapeutic Areas 52
9.1 Musculoskeletal Disorders 54
9.1.1 Analysis of Global Osteoporosis Therapeutics Market and Application of Oral Drug Delivery Systems 54
9.1.2 Analysis of the Global Osteoarthritis Therapeutics Market and Applications of Oral Drug Delivery Systems 55
9.2 Metabolic Disorders 56
9.2.1 Analysis of the Global Type 2 Diabetes Therapeutics Market and Application of Oral Drug Delivery Systems 56
9.2.2 Analysis of the Global Type 1 Diabetes Therapeutics Market and Application of Oral Drug Delivery Systems 57
9.2.3 Analysis of the Global Anti-Obesity Therapeutics Market and Applications of Oral Drug Delivery Systems 58
9.3 Oncology 59
9.3.1 Analysis of the Global Ovarian Cancer Therapeutics Market and Applications of Oral Drug Delivery Systems 59
9.4 Gastrointestinal Disorders 60
9.4.1 Analysis of the Global Ulcerative Colitis Therapeutics Market and Applications of Oral Drug Delivery Systems 60
9.5 Central Nervous System 61
9.5.1 Analysis of the Global Migraine Therapeutics Market and Applications of Oral Drug Delivery Systems 61
9.5.2 Analysis of the Global Parkinsons Disease Therapeutics Market and Applications of Oral Drug Delivery Systems 62
9.6 Infectious Diseases 63
9.6.1 Analysis of the Global Pneumonia Therapeutics Market and Applications of Oral Drug Delivery Systems 63
9.7 Cardiovascular Diseases 64
9.7.1 Analysis of the Global Hypertension Therapeutics Market and Applications of Oral Drug Delivery Systems 64
10 Innovative Oral Drug Delivery Companies Profiles 65
10.1 Chiasma(Israel) Ltd 65
10.1.1 Company Overview 65
10.1.2 Service Portfolio and offerings 65
10.1.3 Product Pipeline 65
10.1.4 Recent Updates Related to Licensing Deals, Strategic Consolidations 65
10.2 Emisphere Technologies Inc 65
10.2.1 Company Overview 65
10.2.2 Service Portfolio and offerings 65
10.2.3 Product Pipeline 66
10.2.4 Recent Updates Related to Licensing Deals, Strategic Consolidations 66
10.3 Merrion Pharmaceuticals Plc 67
10.3.1 Company Overview 67
10.3.2 Service Portfolio and Offerings 67
10.3.3 Product Pipeline 67
10.3.4 Recent Updates Related to Licensing Deals and Strategic Consolidations 68
10.4 Oramed Pharmaceuticals 68
10.4.1 Company Overview 68
10.4.2 Service Portfolio and Offerings 68
10.4.3 Product Pipeline 68
10.4.4 Recent Updates Related to Licensing Deals and Strategic Consolidations 69
10.5 Samyang Corporation 69
10.5.1 Company Overview 69
10.5.2 Service Portfolio and offerings 69
10.5.3 Product Pipeline 70
10.5.4 Recent Updates Related to Licensing Deals and Strategic Consolidations 70
10.6 Unigene Laboratories Inc 70
10.6.1 Company Overview 70
10.6.2 Service Portfolio and Offerings 70
10.6.3 Pipeline Products 71
10.6.4 Recent Updates Related Licensing Deals and Strategic Consolidations 71
10.7 Bone Medical Limited 72
10.7.1 Company Overview 72
10.7.2 Service Portfolio and offerings 72
10.7.3 Product Pipeline 72
10.7.4 Recent Updates Related to Licensing Deals and Strategic Consolidations 72
10.8 Chimerix Inc 73
10.8.1 Company Overview 73
10.8.2 Service Portfolio and Offerings 73
10.8.3 Pipeline Products 73
10.8.4 Recent Updates Related To Licensing Deals and Strategic Consolidations 73
10.9 Mucosis B.V 73
10.9.1 Company Overview 73
10.9.2 Service Portfolio and Offerings 73
10.9.3 Product Pipeline 74
10.9.4 Recent Updates Related to Licensing Deals and Strategic Consolidations 74
10.10 Immupharma Plc 74
10.10.1 Company Profile 74
10.10.2 Service Portfolio and offerings 74
10.10.3 Product Pipeline 74
10.10.4 Recent updates related to licensing deals and strategic consolidations 74
10.11 Access Pharmaceuticals Inc 75
10.11.1 Company Overview 75
10.11.2 Service Portfolio and offerings 75
10.11.3 Product Pipeline 75
10.11.4 Recent updates related to licensing deals and strategic consolidations 76
10.12 ActogeniX NV 76
10.12.1 Company Overview 76
10.12.2 Service Portfolio and offerings 76
10.12.3 Product Pipelines 77
10.12.4 Recent Updates Related to Licensing Deals and Strategic Consolidations 77
10.13 Egalet 78
10.13.1 Company Overview 78
10.13.2 Service Portfolio and offerings 78
10.13.3 Product Pipeline 78
10.13.4 Recent Updates Related to Licensing Deals and Strategic Consolidations 79
10.14 Eurand N.V 79
10.14.1 Company Overview 79
10.14.2 Service Portfolio and Offerings 79
10.14.3 Product Pipeline 79
10.14.4 Recent Updates Related to Licensing Deals and Strategic Consolidations 80
10.15 Supernus Pharmaceuticals,Inc 80
10.15.1 Company Overview 80
10.15.2 Service Portfolio and offerings 80
10.15.3 Product Pipeline 80
10.15.4 Recent updates related to licensing deals and strategic consolidations 80
11 Strategic Consolidations: Licensing, Partnerships , Mergers and Acquisitions (M&As) 81
11.1 Licensing and Partnership Deals In the Oral Drug Delivery Sector 81
11.2 Investments, Funding, Mergers and Acquisition Deals in the Oral Drug Delivery Sector 82
12 Oral Drug Delivery Market Appendix 83
12.1 Market Definitions 83
12.2 Abbreviations 83
12.3 Research Methodology 83
12.3.1 Coverage 84
12.3.2 Secondary Research 84
12.3.3 Primary Research 84
12.3.4 Expert Panel Validation 85
12.4 Contact Us 85
12.5 Disclaimer 85
12.6 Sources 85
Table 1: Oral Drug Delivery Market Forecast (2009-2016) 19
Table 2: Emisphere Technologies- Product Pipeline 66
Table 3: Merrion Pharmaceuticals Product Pipeline 67
Table 4: Oramed Pharmaceuticals Product Pipeline 68
Table 5: Samyang Corporation- Product Pipeline 70
Table 6: Unigene Laboratories Inc - Pipeline Products 71
Table 7: Bone Medical Limited 72
Table 8: Access Pharmaceutical Product Pipeline 75
Table 9: ActogeniX NV Product Pipeline 77
Table 10: Egalet Product Pipeline 78
Table 11: Eurand N.V - Product Pipeline 79
Table 12: Supernus Pharmaceuticals Product Pipeline 80
Figure 1: Global Pharmaceutical Market,by Drug Delivery Methods 10
Figure 2: Role of Drug Delivery in the Pharmaceutical Market 11
Figure 3: Drug Delivery as a Key Lifecycle Management Strategy 12
Figure 4: Pharmaceutical Market, Global , Patent Loss Value ($bn), by Therapy Area (2010-2012) 13
Figure 5: Total Risk of Lost Sales by Major Pharmaceutical Companies due to Patent Expirations 14
Figure 6: Reformulation as a Key Technique for Patent Life Extension 15
Figure 7: Key Drivers for Drug Repositioning 16
Figure 8: Reformulations vs NCE Approvals,(2002-2009) 17
Figure 9:Comparative Study of Oral Drug Delivery Market, by Mode of Administration 2009 18
Figure 10: Oral Drug Delivery Market Forecast (2009-2016) 19
Figure 11: Major Therapeutic Areas For Oral Drug Delivery Systems, By Number of Marketed Drugs,2009 21
Figure 12: Oral Insulin, Pipeline Analysis, by Phase And Indication,(2009-2016) 26
Figure 13: Oral ARBs - Pipeline Analysis by Pipeline And Phase,(2009-2016) 27
Figure 14: Oral Calcitonin, Pipeline Analysis, by Pipeline And Phase,(2009-2016) 28
Figure 15: Oral Bisphosphonates, Pipeline Analysis, by Pipeline And Phase,(2009-2016) 29
Figure 16: Enzyme Inhibitors, Pipeline Analysis, by Pipeline and Phase,(2009-2016) 30
Figure 17: Comparative Analysis of Sustained Release and Other Drug Delivery Methods,(2007-2015) 45
Figure 18: Different Taste Masking Technologies 51
Figure 19: Pharmaceutical Market, Global, Oral Drug Delivery Enabled Products, by Major Companies 52
Figure 20: Oral Drug Delivery Enabled Products, Pipeline Analysis, by Therapy Area 52
Figure 21: Pipeline and Growth Analysis of Various Therapeutic Areas, (2009-2016) 53
Figure 22: Global Osteoporosis Therapeutics Market Forecast 2009-2016 54
Figure 23: Global Type 2 Diabetes Therapeutics Market Forecast 2009-2016 56
Figure 24: Global Type 1 Diabetes Therapeutics Market Forecast 2009-2016 57
Figure 25: Global Anti-Obesity Therapeutics Market Forecast 2009-2016 58
Figure 26: Global Ovarian Cancer Therapeutics Market Forecast 2009-2016 59
Figure 27: Global Ulcerative Colitis Therapeutics Market Forecast 2009-2016 60
Figure 28: Global Migraine Therapeutics Market Forecast 2009-2016 61
Figure 29: Global Parkinsons Disease Therapeutics Market Forecast 2009-2016 62
Figure 30: Global Pneumonia Therapeutics Market Forecast 2009-2016 63
Figure 31: Global Hypertension Therapeutics Market Forecast 2009-2016 64
Figure 32: Licensing and Partnership Deals in the Oral Drug Delivery Sector (2006-2010) 81
Figure 33: Investments, Funding and M&A Deals in the Oral Drug Delivery Sector (2006-2010) 82
1 Table of Contents 3
1.1 List of Tables 7
1.2 List of Figures 8
2 Oral Drug Delivery Market Introduction 9
2.1 GBI Research Report Guidance 9
3 Oral Drug Delivery Market Overview 10
3.1 Global Drug Delivery Market 10
3.2 Drug Delivery as an Essential Component of the Pharmaceutical/Biotechnology Industry 10
3.2.1 Role of Drug Delivery in the Pharmaceutical Market 11
3.3 Patent Expirations and Their Effect on the Pharmaceutical Industry 13
3.3.1 Risk of Lost Sales for Major Pharmaceutical Companies Due to Patent Expiries 14
3.4 Repositioning of Existing Drugs through Reformulations - A Major Lifecycle Management Strategy 15
3.4.1 Repositioning of Marketed or Failed Drugs 15
3.4.2 Repositioning Through Reformulation 16
4 Market Overview - Introduction To The Oral Drug Delivery Market 18
4.1 Comparative Analysis of Oral Drug Delivery with Other Drug Delivery Forms 18
4.2 Oral Drug Delivery Enhanced/Enabled Products - Overview 20
4.2.1 Oral Drug Delivery Product Development Parameters 20
4.2.2 Market Exclusivity for Oral Drug Delivery Enhanced/Enabled Products 20
4.2.3 Major Therapeutic Areas for Oral Drug Delivery Enabled/Enhanced Products 21
5 Technology Landscape - Reformulating Injectable Drugs For Oral Delivery 22
5.1 Technologies Used in Oral Delivery of Peptides and Proteins 22
5.1.1 Oral Delivery Strategies of Peptides and Proteins - Chemical Modifications of Peptides and Protein Drugs 22
5.1.2 Oral Delivery Strategies of Peptides and Proteins - Enzyme Inhibitors 23
5.1.3 Oral Delivery Strategies of Peptides and Proteins - Absorption Enhancements 23
5.1.4 Oral Delivery Strategies of Peptides and Proteins - Using Mucoadhesive Polymers 24
5.1.5 Diabetes and Metabolic Disorders 25
5.1.6 Cardiovascular-related Disorders 27
5.1.7 Osteoporosis/Osteoarthritis and Bone Related Disorders 27
5.1.8 Central Nervous System Related Disorders 30
5.1.9 Oncology 30
5.2 Innovations Related to Oral Vaccine Development 31
5.2.1 Oral Vaccine Research Based Study - Live Bacterial Vectors 32
5.2.2 Oral Vaccine Research Based Study Use of Particulate Formulations 32
5.2.3 Oral Vaccine Research Based Study Use of Non-Toxic Mucosal Adjuvants 32
5.2.4 Oral Vaccine Research Based Study-Transgenic Plants 33
6 Technology Landscape - Nanotechnology in Drug Delivery 34
6.1 Introduction 34
6.2 Application of Nanotechnology 34
6.2.1 NanoDRY and NanoCOAT Technology 34
6.2.2 Polymeric Nano-Delivery System (PNDS) 35
6.2.3 FluidCrystal NP Oral Nanoparticles 35
6.2.4 NanoCrystal Technology 36
7 Technology Landscape - Advances in Oral Prodrug Delivery 37
7.1 Targeted Prodrug Design 37
7.1.1 Prodrug Design Targeting Enzymes 37
7.1.2 Prodrug Design Targeting the Membrane Transporters 39
7.2 Featured Prodrugs- Anti-Viral 41
7.2.1 Oseltamivir 41
7.2.2 Valganciclovir 41
7.2.3 Famciclovir 42
7.2.4 Cidofovir 42
7.2.5 Zanamivir 42
7.3 Respiratory Prodrugs 43
7.3.1 Bambuterol 43
7.4 Featured Prodrugs - Anti-Cancer 43
7.4.1 Gemcitabine 43
7.5 Featured Prodrugs - Central Nervous System 43
7.5.1 Levodopa 43
7.5.2 LY2140023 44
7.6 Featured Prodrugs- Antibiotics 44
7.6.1 Torezolid Phosphate 44
8 Technology Landscape - Advances in Delayed and Controlled Release Delivery 45
8.1 Controlled Release Oral Drugs 45
8.1.1 Dissolution Controlled Release 46
8.1.2 Diffusion Controlled Release 46
8.1.3 Diffusion and Dissolution Controlled Systems 46
8.1.4 Ion-exchange Resins 46
8.1.5 pH - Independent Formulations 46
8.1.6 Osmotically Controlled Release 46
8.1.7 Altered Density Formulations 47
8.1.8 Types of Tablets Formulations Possible for Controlled Release Oral Drugs 47
8.1.9 Challenges and Advantages for Controlled Release Oral Drug Delivery Systems 48
8.1.10 Key Future Applications of Controlled Release Platforms for Oral Therapeutics 49
8.1.11 Orally Disintegrating Tablets 50
8.1.12 Minitablets as a Flexible Drug Delivery System. 50
8.1.13 Taste Masking Technologies for Bitter Tasting Oral Drugs 50
9 Therapeutic Landscape Oral Drug Delivery Systems Across Major Therapeutic Areas 52
9.1 Musculoskeletal Disorders 54
9.1.1 Analysis of Global Osteoporosis Therapeutics Market and Application of Oral Drug Delivery Systems 54
9.1.2 Analysis of the Global Osteoarthritis Therapeutics Market and Applications of Oral Drug Delivery Systems 55
9.2 Metabolic Disorders 56
9.2.1 Analysis of the Global Type 2 Diabetes Therapeutics Market and Application of Oral Drug Delivery Systems 56
9.2.2 Analysis of the Global Type 1 Diabetes Therapeutics Market and Application of Oral Drug Delivery Systems 57
9.2.3 Analysis of the Global Anti-Obesity Therapeutics Market and Applications of Oral Drug Delivery Systems 58
9.3 Oncology 59
9.3.1 Analysis of the Global Ovarian Cancer Therapeutics Market and Applications of Oral Drug Delivery Systems 59
9.4 Gastrointestinal Disorders 60
9.4.1 Analysis of the Global Ulcerative Colitis Therapeutics Market and Applications of Oral Drug Delivery Systems 60
9.5 Central Nervous System 61
9.5.1 Analysis of the Global Migraine Therapeutics Market and Applications of Oral Drug Delivery Systems 61
9.5.2 Analysis of the Global Parkinsons Disease Therapeutics Market and Applications of Oral Drug Delivery Systems 62
9.6 Infectious Diseases 63
9.6.1 Analysis of the Global Pneumonia Therapeutics Market and Applications of Oral Drug Delivery Systems 63
9.7 Cardiovascular Diseases 64
9.7.1 Analysis of the Global Hypertension Therapeutics Market and Applications of Oral Drug Delivery Systems 64
10 Innovative Oral Drug Delivery Companies Profiles 65
10.1 Chiasma(Israel) Ltd 65
10.1.1 Company Overview 65
10.1.2 Service Portfolio and offerings 65
10.1.3 Product Pipeline 65
10.1.4 Recent Updates Related to Licensing Deals, Strategic Consolidations 65
10.2 Emisphere Technologies Inc 65
10.2.1 Company Overview 65
10.2.2 Service Portfolio and offerings 65
10.2.3 Product Pipeline 66
10.2.4 Recent Updates Related to Licensing Deals, Strategic Consolidations 66
10.3 Merrion Pharmaceuticals Plc 67
10.3.1 Company Overview 67
10.3.2 Service Portfolio and Offerings 67
10.3.3 Product Pipeline 67
10.3.4 Recent Updates Related to Licensing Deals and Strategic Consolidations 68
10.4 Oramed Pharmaceuticals 68
10.4.1 Company Overview 68
10.4.2 Service Portfolio and Offerings 68
10.4.3 Product Pipeline 68
10.4.4 Recent Updates Related to Licensing Deals and Strategic Consolidations 69
10.5 Samyang Corporation 69
10.5.1 Company Overview 69
10.5.2 Service Portfolio and offerings 69
10.5.3 Product Pipeline 70
10.5.4 Recent Updates Related to Licensing Deals and Strategic Consolidations 70
10.6 Unigene Laboratories Inc 70
10.6.1 Company Overview 70
10.6.2 Service Portfolio and Offerings 70
10.6.3 Pipeline Products 71
10.6.4 Recent Updates Related Licensing Deals and Strategic Consolidations 71
10.7 Bone Medical Limited 72
10.7.1 Company Overview 72
10.7.2 Service Portfolio and offerings 72
10.7.3 Product Pipeline 72
10.7.4 Recent Updates Related to Licensing Deals and Strategic Consolidations 72
10.8 Chimerix Inc 73
10.8.1 Company Overview 73
10.8.2 Service Portfolio and Offerings 73
10.8.3 Pipeline Products 73
10.8.4 Recent Updates Related To Licensing Deals and Strategic Consolidations 73
10.9 Mucosis B.V 73
10.9.1 Company Overview 73
10.9.2 Service Portfolio and Offerings 73
10.9.3 Product Pipeline 74
10.9.4 Recent Updates Related to Licensing Deals and Strategic Consolidations 74
10.10 Immupharma Plc 74
10.10.1 Company Profile 74
10.10.2 Service Portfolio and offerings 74
10.10.3 Product Pipeline 74
10.10.4 Recent updates related to licensing deals and strategic consolidations 74
10.11 Access Pharmaceuticals Inc 75
10.11.1 Company Overview 75
10.11.2 Service Portfolio and offerings 75
10.11.3 Product Pipeline 75
10.11.4 Recent updates related to licensing deals and strategic consolidations 76
10.12 ActogeniX NV 76
10.12.1 Company Overview 76
10.12.2 Service Portfolio and offerings 76
10.12.3 Product Pipelines 77
10.12.4 Recent Updates Related to Licensing Deals and Strategic Consolidations 77
10.13 Egalet 78
10.13.1 Company Overview 78
10.13.2 Service Portfolio and offerings 78
10.13.3 Product Pipeline 78
10.13.4 Recent Updates Related to Licensing Deals and Strategic Consolidations 79
10.14 Eurand N.V 79
10.14.1 Company Overview 79
10.14.2 Service Portfolio and Offerings 79
10.14.3 Product Pipeline 79
10.14.4 Recent Updates Related to Licensing Deals and Strategic Consolidations 80
10.15 Supernus Pharmaceuticals,Inc 80
10.15.1 Company Overview 80
10.15.2 Service Portfolio and offerings 80
10.15.3 Product Pipeline 80
10.15.4 Recent updates related to licensing deals and strategic consolidations 80
11 Strategic Consolidations: Licensing, Partnerships , Mergers and Acquisitions (M&As) 81
11.1 Licensing and Partnership Deals In the Oral Drug Delivery Sector 81
11.2 Investments, Funding, Mergers and Acquisition Deals in the Oral Drug Delivery Sector 82
12 Oral Drug Delivery Market Appendix 83
12.1 Market Definitions 83
12.2 Abbreviations 83
12.3 Research Methodology 83
12.3.1 Coverage 84
12.3.2 Secondary Research 84
12.3.3 Primary Research 84
12.3.4 Expert Panel Validation 85
12.4 Contact Us 85
12.5 Disclaimer 85
12.6 Sources 85
List of Tables
Table 1: Oral Drug Delivery Market Forecast (2009-2016) 19
Table 2: Emisphere Technologies- Product Pipeline 66
Table 3: Merrion Pharmaceuticals Product Pipeline 67
Table 4: Oramed Pharmaceuticals Product Pipeline 68
Table 5: Samyang Corporation- Product Pipeline 70
Table 6: Unigene Laboratories Inc - Pipeline Products 71
Table 7: Bone Medical Limited 72
Table 8: Access Pharmaceutical Product Pipeline 75
Table 9: ActogeniX NV Product Pipeline 77
Table 10: Egalet Product Pipeline 78
Table 11: Eurand N.V - Product Pipeline 79
Table 12: Supernus Pharmaceuticals Product Pipeline 80
List of Figures
Figure 1: Global Pharmaceutical Market,by Drug Delivery Methods 10
Figure 2: Role of Drug Delivery in the Pharmaceutical Market 11
Figure 3: Drug Delivery as a Key Lifecycle Management Strategy 12
Figure 4: Pharmaceutical Market, Global , Patent Loss Value ($bn), by Therapy Area (2010-2012) 13
Figure 5: Total Risk of Lost Sales by Major Pharmaceutical Companies due to Patent Expirations 14
Figure 6: Reformulation as a Key Technique for Patent Life Extension 15
Figure 7: Key Drivers for Drug Repositioning 16
Figure 8: Reformulations vs NCE Approvals,(2002-2009) 17
Figure 9:Comparative Study of Oral Drug Delivery Market, by Mode of Administration 2009 18
Figure 10: Oral Drug Delivery Market Forecast (2009-2016) 19
Figure 11: Major Therapeutic Areas For Oral Drug Delivery Systems, By Number of Marketed Drugs,2009 21
Figure 12: Oral Insulin, Pipeline Analysis, by Phase And Indication,(2009-2016) 26
Figure 13: Oral ARBs - Pipeline Analysis by Pipeline And Phase,(2009-2016) 27
Figure 14: Oral Calcitonin, Pipeline Analysis, by Pipeline And Phase,(2009-2016) 28
Figure 15: Oral Bisphosphonates, Pipeline Analysis, by Pipeline And Phase,(2009-2016) 29
Figure 16: Enzyme Inhibitors, Pipeline Analysis, by Pipeline and Phase,(2009-2016) 30
Figure 17: Comparative Analysis of Sustained Release and Other Drug Delivery Methods,(2007-2015) 45
Figure 18: Different Taste Masking Technologies 51
Figure 19: Pharmaceutical Market, Global, Oral Drug Delivery Enabled Products, by Major Companies 52
Figure 20: Oral Drug Delivery Enabled Products, Pipeline Analysis, by Therapy Area 52
Figure 21: Pipeline and Growth Analysis of Various Therapeutic Areas, (2009-2016) 53
Figure 22: Global Osteoporosis Therapeutics Market Forecast 2009-2016 54
Figure 23: Global Type 2 Diabetes Therapeutics Market Forecast 2009-2016 56
Figure 24: Global Type 1 Diabetes Therapeutics Market Forecast 2009-2016 57
Figure 25: Global Anti-Obesity Therapeutics Market Forecast 2009-2016 58
Figure 26: Global Ovarian Cancer Therapeutics Market Forecast 2009-2016 59
Figure 27: Global Ulcerative Colitis Therapeutics Market Forecast 2009-2016 60
Figure 28: Global Migraine Therapeutics Market Forecast 2009-2016 61
Figure 29: Global Parkinsons Disease Therapeutics Market Forecast 2009-2016 62
Figure 30: Global Pneumonia Therapeutics Market Forecast 2009-2016 63
Figure 31: Global Hypertension Therapeutics Market Forecast 2009-2016 64
Figure 32: Licensing and Partnership Deals in the Oral Drug Delivery Sector (2006-2010) 81
Figure 33: Investments, Funding and M&A Deals in the Oral Drug Delivery Sector (2006-2010) 82
Upcoming Reports:
|
Cancer Profiling And Pathways Market - Global Industry Analysis, Market Size, Share, Growth, Trends, And Forecast, 2012 - 2018
By - Transparency Market Research
Cancer cells exhibit a fundamentally modified metabolism that creates an environment in the body to support the growth of tumors and malignancy. In-depth understanding of the biochemical characters of cancer has facilitated the understanding and implementation of several different cancer profiling platforms.
Deciphering the scope of altered metabolism of cancer cells, its relevance in disease pathogenesis, and its further potential in the discovery of suitable therapeutics, thus, demands development in technologies for the identification of modified enzymes and cellular...
|
|
Influenza Vaccine Market - Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth And Forecasts 2012 - 2018
By - Transparency Market Research
Influenza Vaccine is also called as flu shot and is used for protection against influenza virus. An influenza vaccine is a combination of three influenza viruses namely, influenza type A with H3N2 virus strain, influenza type A with H1N1 virus strain and influenza type B virus strain.
Over the recent years, the Influenza Vaccine market has witnessed double digit growth rate due to fear of an impending pandemic. The Influenza Vaccine market has grown at a CAGR of approximately 65% between 2008 and 2010 due to the havoc caused by H1N1 virus. However, H1N1 flu vaccine...
|
|
Bio-Based Levulinic Acid Market - Global Industry Analysis, Potential Applications, Downstream Derivatives Market Size, Share, Trends, Growth And Forecast 2009 - 2019
By - Transparency Market Research
New molecules developed by Segetis, in Minnesota based on esters of levulinic acid made from using bio based hydroxyl compounds and corn cobs are known as levulinic ketals. These can be used to produce a series of products such as plasticizers, polyols for polyurethane foams and solvents. Segetis are constructing a new toll manufacturing plant for their new ketals chemistry in the Midwest and the construction of which was expected to be completed by the end of 2011. Products entering the market would start with solvents. While polyols is expected to be the last to enter in...
|
Research Assistance
We will be happy to help you find what you need.
Please call us or write us:
Please call us or write us:
866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Email: sales@researchmoz.com
Select License type:
Share this report
Latest Reports
- Bed Linen Markets in the World to 2017 - Market Size, Trends, and Forecasts
- Bed Linen Markets in Europe to 2017 - Market Size, Trends, and Forecasts
- Bed Linen Markets in Eastern Europe to 2017 - Market Size, Trends, and Forecasts
- Bed Linen Markets in Western Europe to 2017 - Market Size, Trends, and Forecasts
- Bed Linen Markets in Asia to 2017 - Market Size, Trends, and Forecasts
- Bed Linen Markets in Americas to 2017 - Market Size, Trends, and Forecasts
- Bed Linen Markets in Africa to 2017 - Market Size, Trends, and Forecasts
- Bed Linen Markets in the Top 10 Global Countries to 2017 - Market Size, Trends, and Forecasts
- Bed Linen Markets in the Top 5 European Countries to 2017 - Market Size, Trends, and Forecasts
- Bed Linen Markets in the Top 5 Asian countries to 2017 - Market Size, Trends, and Forecasts
Related News
|
One-third of Massachusetts Hospitals Facing Financial Downturn
Sep 14, 2012
The healthcare Industry in the United States works as a separate entity and many of the healthcare services are privately owned and operated. Healthcare has always been a topic of debate for the U.S. government because policy makers argue that the system is not delivering value for money services. In fact government is spending twice as much on life expectancy and infant mortality rate...
|
|
Now At-Home TB Diagnosis Looks Possible
Sep 14, 2012
According to a recent research published in Nature Chemistry, scientists have revealed that a certain sensitive fluorescent molecule is capable of efficiently and quickly tracing TB (tuberculosis) bacteria from the sputum samples.
The year 2010 registered approximately 4000 deaths per day because of TB. TB diagnosis takes a few weeks and the disease being contagious puts others at...
|
|
China Economy Gets USD 157 Billion Stimulus with Sanction for 60 Infrastructure Projects
Sep 14, 2012
Seen as a much required economical stimulus to revive the economy stuck in the worst slowdown in the past three years, China has approved 60 different infrastructure projects valued at more than USD 150 billion. Immediately after the official confirmation of the decision, stocks of major industries such as cement and steel have seen a rise on hopes generated by plans to build ports, highways,...
|
|
Battling against flu, vaccination necessary for health workers
Sep 14, 2012
To battle against flu this season, health officials have tightened their resolve to get more health care workers vaccinated. Flu is a disease that transfers from one to another. Keeping this in mind health officials want every worker in the health care department to get vaccinated. By doing this, it will lessen the chances of others getting affected by this disease.
Health officials...
|
|
Japan to Cut Import Duties on Indian Generic Drugs Imports
Sep 14, 2012
The 44th ASEAN Economic Ministers Meeting held last week in Cambodia has certainly brought good news for the Indian Pharmaceuticals industry. During the meeting on the sidelines of the 44th ASEAN Economic Ministers Meet, Indian Commerce and Industry Minister Anand Sharma brought up the issue with his Japanese counterpart Yukio Edano. Yukio Edano is the minister of economy, trade and Industry...
|
